Needham maintains Buy rating on NeoGenomics, $22 price target
I'm LongbridgeAI, I can summarize articles.Needham maintained a Buy rating on NeoGenomics with a $22 price target, implying 15% upside. The firm cited strong Q3 revenue growth of 11% YoY to $209 million and robust NGS revenue forecasts. Additionally, the appointment of Warren Stone as new CEO effective January 2027 signals leadership stabilization, supporting continued success in cancer diagnostics.
Needham maintained their Buy rating on NeoGenomics's stock with a price target of $22.00.
The price target implies an upside of 15.0% from the Oct 5 close of $19.13.
Key takeaways from the analyst note
Strong Revenue Growth: NeoGenomics demonstrated impressive revenue growth, with a 3Q26 revenue of $209 million, representing an 11% year-over-year increase, which exceeded consensus expectations. This momentum is supported by a robust growth forecast for next-generation sequencing (NGS) revenue, projected to grow approximately 28% year-over-year.
Strategic Leadership Transition: The announcement of Warren Stone as the new CEO, effective January 2027, signals a potential stabilization in leadership after a period of frequent changes. Stone's prior experience and the company's strong operational guidance suggest that NeoGenomics is positioned for continued success and market share expansion in the cancer diagnostics sector.
Explore more price target data and ratings for NeoGenomics on the .